Considering all our findings, the potential to increase tumor susceptibility to PD‐1/PD‐L1 inhibitors through PD‐L1 upregulation, enhanced antigen presentation via HLA‐I, and other influencing factors (amplifying IFNγ's cytotoxic effect) support the promising role of combining TAK‐228 with ICI in patients with advanced BC. This evidence concerns the gene PDCD1 and neoplasm.